phosphate binder
Jump to navigation
Jump to search
Adverse effects
- cardiovascular safety of sevelamer same as calcium acetate[2]
- hospital admission rates lowest for Velphoro 8.0 per 100 member months vs Fosrenol 9.9, Auryxia 9.5, sevelamer 10.5, Phosl0 11.3[3]
More general terms
More specific terms
- aluminum hydroxide (Alternagel, Amphojel, Alu-Cap, Dialume, AlH3OH)
- calcium acetate (PhosLo)
- calcium carbonate (Tums, Oscal, Oyst-Cal)
- ferric citrate (Auryxia)
- lanthanum carbonate (La2[CO3]3, Fosrenol)
- sevelamer (Renagel, Genzyme, Renvela)
- sucroferric oxyhydroxide (Velphoro)
References
- ↑ Prescriber's Letter 22(8): 2015 (subscription needed) Comparison of Phosphate Binders Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=310810&pb=PRL http://www.prescribersletter.com
- ↑ 2.0 2.1 Spoendlin J, Paik JM, Tsacogianis T et al Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. Published online May 6, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31058913 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2732117
- ↑ 3.0 3.1 Monaco K Phosphate Binder Type Matters in Dialysis - Hospital admission rates, healthcare costs varied according to binder prescribed MedPage Today. March 28, 2020 https://www.medpagetoday.com/meetingcoverage/nkf/85667
Lindemann K et al An Observational Analysis of Hospital Admissions and Total Member Costs Associated with the Use of Various Phosphate Binders Used in Dialysis Patients Included in ESCOs. National Kidney Foundation (NKF) 2020; Abstract 209.